

MediGene AG



Company Profile

MediGene AG is a publicly quoted German biopharmaceutical company headquartered in Martinsried, Munich, with subsidiary MediGene, Inc., in San Diego, California. MediGene combines a broad technology platform with products in pre-clinical and clinical development.

The company's multi-tiered business strategy has generated a number of proprietary enabling technologies to create a portfolio of novel therapeutic opportunities and drug candidates for in-house development and out-licensing.

MediGene's Product Sale



Stock Performance



Key Stock Data (as of 11/11/2002)


All Figures in EURO, unless otherwise noted

Price	3.91
52 week high (11/22/2001)	25.65
52 week low (10/10/2002)	2.71
Shares outstanding (mil)	11.181
Market capitalization (mil)	43.82

Exchange: Neuer Markt


Revenue Growth

thousands of DM



R&D Expenses

thousands of DM



Management

Dr. Peter Heinrich	□	Chief Executive Officer
Dr. Johanna Holldack	□	Chief Operating Officer
Alexander Dexne	□	Chief Financial Officer
Dr. Frank Tufaro	□	Managing Director (MediGene, Inc.)

Highlights from the First Nine Months 2002

Leuprogel®: Marketing authorization application for the one-month and three-months depot product has been submitted to the German authorities. MediGene is the first German biotech company that has drug candidates in the approval process.

Polyphenon®E: The first phase 3 trial has been successfully completed, a follow-up phase 3 trial has been initiated.

G207: Orphan Drug Status granted by the FDA.

NV 1020: Phase 1/2 trial completed with positive results. Two US patents on MediGene's HSV products have been granted.

CVLP vaccine: Patients recruitment for phase 1/2 trial completed.

rAAV vaccine: Two US patents granted.

Etomoxir: Development project was discontinued, because the phase 2 trial which had been prematurely finished did not show the expected results regarding efficacy, but led to side effects in some individual cases.

In August 2002, MediGene announced the planned spin-off of the cardiological drug discovery program, which will enable the company to focus on tumor diseases in the future. In October 2002, gained Evotec OAI AG as a partner and co-founder for the planned new company.

New Products Coming to Market

Product	Clinical Phase			Approval	Max. Sales Potential ¹⁾
	1	2	3		
Leuprogel	→			→	> 50 million €
Polyphenon	→			→	> 50 million €
G207	→ ³⁾	→			> 300 million €
CVLP-vaccine	→ ⁴⁾				> 250 million €
NV1020	→ ⁴⁾				> 200 million €
rAAV-vaccine	→ ⁴⁾				> 200 million €
Chance of reaching the market ²⁾ :	10-30%	40-60%	60-80%	90%	

¹⁾ per year; source: Analyst's estimates
²⁾ Source: Analyst's estimates
³⁾ Phase 1b/2
⁴⁾ Phase 1/2

Analyst Coverage

- Mr. Steven Cox ☐ Commerzbank Securities
- Dr. Andreas Bischof ☐ Credit Agricole Indosuez
- Dr. Stephen McGarry ☐ Goldman Sachs International
- Mr. Samir Devani ☐ J.P.Morgan Chase H&Q Flemings
- Mr. Daniel Mahony ☐ Morgan Stanley Dean Witter

Contact Information

MediGene AG

Dr. Peter Heinrich, CEO
 Lochhamer Str. 11
 82152 Martinsried, Germany

Tel: 49-89-85 65 290
 Fax: 49-89-85 65 2920
 Email: heinrich@medigene.de